263 related articles for article (PubMed ID: 33990592)
1. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.
Ochi Y; Yoshida K; Huang YJ; Kuo MC; Nannya Y; Sasaki K; Mitani K; Hosoya N; Hiramoto N; Ishikawa T; Branford S; Shanmuganathan N; Ohyashiki K; Takahashi N; Takaku T; Tsuchiya S; Kanemura N; Nakamura N; Ueda Y; Yoshihara S; Bera R; Shiozawa Y; Zhao L; Takeda J; Watatani Y; Okuda R; Makishima H; Shiraishi Y; Chiba K; Tanaka H; Sanada M; Takaori-Kondo A; Miyano S; Ogawa S; Shih LY
Nat Commun; 2021 May; 12(1):2833. PubMed ID: 33990592
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Ma CC; Chai Y; Chen HL; Wang X; Gao Y; Hu WL; Xiang X
J Int Med Res; 2020 May; 48(5):300060520919237. PubMed ID: 32366154
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
[TBL] [Abstract][Full Text] [Related]
4. Genetic landscape of chronic myeloid leukemia.
Ochi Y
Int J Hematol; 2023 Jan; 117(1):30-36. PubMed ID: 36477676
[TBL] [Abstract][Full Text] [Related]
5. Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
Shoumariyeh K; Hussung S; Niemöller C; Bleul S; Veratti P; Follo M; Riba J; Philipp U; Palmer JM; Pfeifer D; Pantic M; Meggendorfer M; Hackanson B; Finke J; Haferlach T; Duyster J; Miething C; Becker H; von Bubnoff N
Br J Haematol; 2020 Sep; 190(6):e339-e343. PubMed ID: 32579287
[No Abstract] [Full Text] [Related]
6. [Clinical significance of clonal evolution in chronic myeloid leukemia].
Ochi Y
Rinsho Ketsueki; 2023; 64(5):369-375. PubMed ID: 37271527
[TBL] [Abstract][Full Text] [Related]
7. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
8. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
9. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
10. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Zhao LJ; Wang YY; Li G; Ma LY; Xiong SM; Weng XQ; Zhang WN; Wu B; Chen Z; Chen SJ
Blood; 2012 Mar; 119(12):2873-82. PubMed ID: 22318203
[TBL] [Abstract][Full Text] [Related]
11. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S; Dufva O; Ianevski A; Ghimire B; Koski J; Maliniemi P; Thomson D; Schreiber A; Heckman CA; Koskenvesa P; Korhonen M; Porkka K; Branford S; Aittokallio T; Kankainen M; Mustjoki S
Leukemia; 2021 Apr; 35(4):1087-1099. PubMed ID: 32782381
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
13. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
[TBL] [Abstract][Full Text] [Related]
14. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
[TBL] [Abstract][Full Text] [Related]
15. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
17. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Sakai K; Ishikawa Y; Mori Y; Kobayashi M; Iriyama C; Ozawa Y; Suzuki T; Minami Y; Ishikawa K; Kaneda N; Naoe T; Kiyoi H
Int J Hematol; 2011 Feb; 93(2):237-242. PubMed ID: 21264552
[TBL] [Abstract][Full Text] [Related]
18. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
[TBL] [Abstract][Full Text] [Related]
19. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
[TBL] [Abstract][Full Text] [Related]
20. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
Ko TK; Javed A; Lee KL; Pathiraja TN; Liu X; Malik S; Soh SX; Heng XT; Takahashi N; Tan JHJ; Bhatia R; Khng AJ; Chng WJ; Sia YY; Fruman DA; Ng KP; Chan ZE; Xie KJ; Hoi Q; Chan CX; Teo ASM; Velazquez Camacho O; Meah WY; Khor CC; Ong CTJ; Soon WJW; Tan P; Ng PC; Chuah C; Hillmer AM; Ong ST
Blood; 2020 Jun; 135(26):2337-2353. PubMed ID: 32157296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]